載入中
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
收盤時
US$11.79
−US$1.21 · -9.31%
盤中時間採用ET。市場資料可能有所延遲。
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
日內區間
目前US$11.79
52週區間
目前US$11.79
盤中時間採用ET。市場資料可能有所延遲。
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
日內區間
目前US$11.79
52週區間
目前US$11.79
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.7億 USD | 2.27億 USD | 2.51億 USD | 4.78億 USD | 3.14億 USD |
| 銷貨成本 | 3152.1萬 USD | 3854.9萬 USD | 5400.5萬 USD | 2.04億 USD | 1.3億 USD |
| 毛利 | 1.39億 USD | 1.88億 USD | 1.97億 USD | 2.73億 USD | 1.84億 USD |
| 研究與開發 | 2.44億 USD | 4.24億 USD | 5.81億 USD | 10.53億 USD | 11.5億 USD |
| 銷售、一般及管理費用 | 1.83億 USD | 2.46億 USD | 3.85億 USD | 14.3億 USD | 8.63億 USD |
| 營業費用 | 4.54億 USD | 7.48億 USD | 10.62億 USD | 24.82億 USD | 20.13億 USD |
| 利息收入 | 2261.6萬 USD | 3861.2萬 USD | 5721.7萬 USD | 2026.2萬 USD | 83.7萬 USD |
| 利息支出 | — | 9.4萬 USD | 9.3萬 USD | 10.6萬 USD | 237.3萬 USD |
| 折舊和攤銷 | 5899萬 USD | 6302萬 USD | 7155.4萬 USD | 4255.2萬 USD | 2907.6萬 USD |
| 營業利益 | −3.15億 USD | −5.6億 USD | −8.64億 USD | −22.09億 USD | −18.28億 USD |
| 淨利 | −3.13億 USD | −5.47億 USD | −8.93億 USD | −21.05億 USD | −18.3億 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
